ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

A new study found cyclosporine was no more effective than infliximab in patients with acute, severe ulcerative colitis refractory to intravenous steroids, according to a report by Internal Medicine ...

The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...

News and commentary from the world of gastroenterology and hepatology ...

Please provide your email address to receive an email when new articles are posted on . Use of a second anti-TNF — IV or subcutaneous agent — resulted in early response and long-term remission among ...

On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA (infliximab-dyyb), a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative ...

JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) ...

LONDON, Dec 17 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Wednesday it had recommended the use of Remicade as an option for treating acute exacerbations of ulcerative ...

Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...

Please provide your email address to receive an email when new articles are posted on . Infliximab induction and maintenance were associated with “potentially improved efficacy outcomes” vs.